Radiation plus Chemo-Immunotherapy shows promise in High-Risk breast cancer trial
NCT ID NCT07254858
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common, high-risk breast cancer type (HR+/HER2-). About 302 participants will be randomly assigned to receive either chemo-immunotherapy alone or with the added radiation. The goal is to see if the combination leads to a higher rate of tumor disappearance by the time of surgery and better long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could two years of hormone therapy be enough for some breast cancers?
- Could a targeted drug re-sensitize resistant breast cancer?
- AI reads MRI scans to predict who will benefit from chemo
- Three-Drug cocktail aims to shrink breast tumors before surgery
- Radioactive 'Smart Bombs' target Hard-to-Treat cancers